Cellply Lands €7.15M to Accelerate Cell Therapy

The big picture: Cellply, a Bologna-based DeepTech startup, has secured €7.15 million in its latest funding round. The company develops analytical tools for the characterization of cancer immunotherapies, cell therapies, and cell-based biotherapeutics.

Why it matters:

• Accelerated Development: The funding provides resources to accelerate commercial expansion and advance innovative quality control solutions, crucial for broader adoption of Advanced Therapy Medicinal Products (ATMPs).
• Enhanced Potency: Cellply’s technology enables rapid development of new immunotherapies and cell-based therapies with enhanced potency and persistence.
• Streamlined Quality Control: The capital will advance next-generation automated functional testing solutions, aiming to deliver high precision in cell potency assessment and streamline batch release processes.

How it works:

• Single-Cell Resolution: Cellply creates solutions capable of characterizing therapeutic modalities at single-cell resolution.
• VivaCyte Platform: Its flagship product, VivaCyte®, is an analytical system for the discovery and process development of cell therapies, offering unprecedented resolution and scale.
• Integrated Technology: VivaCyte® combines patented microfluidic technology, AI-powered automated image analysis, and comprehensive automation with dedicated software.

The catch: The cell and gene therapy market is highly competitive, with numerous companies vying to reduce development costs and accelerate timelines. While Cellply’s technology offers significant advancements in characterization and quality control, widespread adoption will depend on demonstrating superior efficiency and cost-effectiveness compared to existing and emerging solutions. The complexity of ATMP manufacturing and regulatory hurdles also present ongoing challenges.